Clover Meds: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Clover Meds’ website, https://clovermeds.com, FDA Establishment Identifier (FEI) 3044175705, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “1. The compounded semaglutide and tirzepatide products displayed on your website identify “Clover Meds” on the pictured label, suggesting Clover Meds is the compounder of those drugs when in fact it is not.”

2. 2

   “2. Your website claims that the compounded drug products it offers are sourced from “FDA-licensed Facilities.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&C Act does not establish an "FDA-approved" or "FDA-licensed” designation for pharmacies or outsourcing facilities.”

3. 3

   “While an entity may elect to register with FDA as an outsourcing facility under section 503B of the FD&C Act [21 U.S.C. § 353b], this registration does not constitute FDA approval or licensure of the facility or its compounded drug products. Neither compounders operating under section 503A nor outsourcing facilities operating under section 503B undergo FDA premarket review or approval of their compounded drug products.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

clovermeds.com returned a live site on 2026-08-09 titled "Virtual Weight Loss Clinic - Clover Meds™", carrying a new-patient promotion ("New patients use code SUMMER2026 for 10% OFF") and product routes for compounded semaglutide, compounded tirzepatide, testosterone therapy and NAD+; no price is posted on the landing page itself.

There is a specific reason this phrasing is worth pausing on. "FDA-licensed Facilities" is plural and anonymous — it does not name a pharmacy you could go and check, it gestures at a category and asks you to accept that the category has been vetted. FDA's footnote here is the clearest statement of why that fails anywhere in this dataset: a compounder can register with FDA as a 503B outsourcing facility, and registration is not approval or licensure of the facility or of anything it makes. Neither 503A compounders nor 503B outsourcing facilities go through premarket review. So the reassurance was doing two jobs — telling you the supply chain is supervised, and letting the supplier stay unnamed — and the letter removes the first without filling in the second. That is a gap in what you know about who fills your order, not a statement about the drug in the vial. Combined with the label finding, the honest read is simply that this page did not, at the time FDA looked, let you identify who compounded what you were paying for.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Clover Meds failed to respond.